68Ga-HX01

68Ga-HX01 is a radiopharmaceutical PET imaging agent designed for noninvasive visualization of tumor angiogenesis. It is a dual-targeting peptide tracer labeled with the radionuclide gallium-68 (68Ga), specifically engineered to bind both integrin αvβ3 and aminopeptidase N (CD13), which are overexpressed in tumor neovasculature and certain malignant tissues. The molecule incorporates RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) peptide motifs to achieve high affinity for its targets. In clinical studies, 68Ga-HX01 demonstrated favorable pharmacokinetics with rapid renal excretion, reliable safety profile, and effective detection of malignant lesions in patients. Its primary indication is PET-based diagnosis and monitoring of malignancies by targeting tumor-associated angiogenesis[1][2][3][7].